Randomized trial · people
Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with heart disease and excess weight but no diabetes, weekly semaglutide 2.4 mg led to fewer heart-related deaths, heart attacks and strokes than placebo, and more people stopped it because of side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 17604
- Published
- 2023
- Journal
- N Engl J Med
What they tested
Does weekly semaglutide lower the risk of heart-related death, heart attack or stroke in people with heart disease and excess weight who do not have diabetes?
How the study was done
A double-blind, randomized, placebo-controlled trial at many centers in 17,604 adults aged 45 or older with existing heart disease, a body-mass index of 27 or greater and no diabetes. It compared once-weekly 2.4 mg semaglutide shots with placebo (a dummy shot), and average follow-up was 39.8±9.4 months.

Model. Individual results vary.
What they found
The main outcome was the first of three events: death from heart causes, a nonfatal heart attack or a nonfatal stroke. It happened in 569 of 8803 people (6.5%) on semaglutide and 701 of 8801 people (8.0%) on placebo. The hazard ratio, a measure of risk over time on semaglutide versus placebo, was 0.80, with a likely range running from 0.72 up to 0.90, and the gap was statistically significant (P<0.001). Side effects made 1461 people (16.6%) on semaglutide stop the treatment for good, compared with 718 (8.2%) on placebo.
What it doesn’t show
It included only people aged 45 or older who already had heart disease, so it does not show the effect in people without heart disease or in people with diabetes. It tested one dose, and the trial was funded by Novo Nordisk.
The paper
Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.